IDXX IDEXX Laboratories, Inc.

IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of

On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the […]

IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...

IDEXX Laboratories (IDXX) drew fresh attention after expanding its Faecal Dx antigen testing platform in the United Kingdom to cover taeniid tapeworms, including Taenia and Echinococcus species, during routine veterinary visits. Recent moves by IDEXX Laboratories, including the Faecal Dx expansion and the CoVetAI acquisition, come as the share price sits at US$506.48. The year-to-date share price return is down 24.4%, but the 3-year total shareholder return remains positive at 15.46%,...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1.3% and the actively trad

IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...

If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.

Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.

Despite trailing the Dow over the past year, IDEXX still has Wall Street on its side, with analysts maintaining a cautiously optimistic view on its future prospects.

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.

IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre

IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...

Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

Aug 6 (Reuters) - Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and

Moby summary of IDEXX Laboratories, Inc.'s Q2 2026 earnings call

IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.

IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s

IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad

IDEXX Laboratories Inc. (NASDAQ:IDXX) shares rose nearly 4% in pre-market trading after the veterinary diagnostics company reported second-quarter 2026 results that exceeded Wall Street expectations and increased its full-year earnings guidance.

Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Corporate responsibility report puts IDEXX Laboratories (IDXX) in focus IDEXX Laboratories (IDXX) recently released its 2025 Corporate Responsibility Report, drawing attention to the stock as investors assess how the company’s plans for pet diagnostics, employees, and sustainability fit into its long term outlook. See our latest analysis for IDEXX Laboratories. The recent 6.3% 30 day share price return contrasts with IDEXX Laboratories’ share price being down 15.0% year to date, while the 3...

IDEXX Laboratories (NASDAQ:IDXX) released its 2025 Corporate Responsibility Report, outlining progress across innovation, workforce development, and environmental initiatives that support the company’s long-term growth strategy. Key Investor TakeawaysIDEXX published its 2025 Corporate Responsibility Report, highlighting advances in innovation, employee development, and sustainability.

Elanco Animal Health (ELAN) seems "best-positioned name" into the Q2 print, with IDEXX Laboratories

IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.

ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.

IDEXX Laboratories will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.